Investigating how a protein affects bone disease and immune suppression in multiple myeloma
Binding of MMP13 to Immune Checkpoint Receptor PD-1H links Bone Disease with Immune Suppression in Multiple Myeloma
This study is looking at how a protein called MMP-13 affects bone health in people with multiple myeloma, a type of cancer, to help find new ways to protect their bones from damage.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Columbia University Health Sciences NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-10889051 on NIH RePORTER |
What this research studies
This research focuses on understanding the role of matrix metalloproteinase 13 (MMP-13) in causing bone disease in patients with multiple myeloma, a type of cancer. The study examines how MMP-13 activates osteoclasts, the cells responsible for bone resorption, leading to severe bone damage. By using mouse models and analyzing patient samples, researchers aim to uncover the mechanisms by which MMP-13 contributes to bone lesions and immune suppression. The findings could lead to new therapeutic strategies to improve bone health in affected patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with multiple myeloma who are experiencing bone disease or related complications.
Not a fit: Patients with multiple myeloma who do not have bone disease or those with other unrelated conditions may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that prevent bone damage and improve the quality of life for patients with multiple myeloma.
How similar studies have performed: Previous research has shown that targeting similar pathways in cancer-related bone diseases can lead to significant improvements, suggesting potential for success in this approach.
Where this research is happening
New York, United States
- Columbia University Health Sciences — New York, United States (Active)
Researchers
- Principal investigator: Lentzsch, Suzanne — Columbia University Health Sciences
- Study coordinator: Lentzsch, Suzanne
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.